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Abstract
Aim: This study is aimed to evaluate the relationship between serum vitamin D levels and metabolic syndrome
in hemodialysis patients.
Materials and Methods: This study was conducted with participation of 80 patients undergoing hemodialysis
for more than 6 months three times a week, aged > 18 years. Their height, dry weight, waist circumference
were measured. Biochemical parameters such as serum 25-hydroxyvitamin D, lipid profile, and fasting blood
glucose were analyzed. Metabolic syndrome was defined using the National Cholesterol Education Program
Adult Treatment Panel III criteria. Severe vitamin D deficiency, 25 (OH) vitamin D < 5 ng/ml; mild vitamin D
deficiency, 25 (OH) vitamin D 5-15 ng/ml; vitamin D insufficiency, 25 (OH) vitamin D 16-30 ng/ml, and vitamin D
sufficiency, 25 (OH) vitamin D > 30 ng/ml were categorized. Statistical analysis of the data was performed with
the use of SPSS version 21.0.
Results: 48.4% of hemodialysis patients were identified to have metabolic syndrome. According to the serum
levels of vitamin D; 35.0% of patients had severe vitamin D deficiency, 37.4% of patients had mild vitamin D
deficiency, 18.8% of patients had vitamin D insufficiency and 8.8% of patients had vitamin D sufficiency
(> 30 ng/ml). Vitamin D insufficiency was significantly associated with metabolic syndrome and central obesity.
Conclusions: Deficiency/insufficiency is observed in serum 25-hydroxyvitamin D levels in hemodialysis patients.
Vitamin D insufficiency is associated with metabolic syndrome.
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Problem statement and analysis of the
latest research
Metabolic syndrome is defined as a set of risk factors that in-
clude insulin resistance, hypertension, high triglyceride levels,
lower high-density lipoprotein cholesterol levels, and obesity
(particularly central adiposity) [1]. Metabolic syndrome has
risk factors for cardiovascular diseases, type 2 diabetes, and
progression of hepatic and renal disorders [2].
Vitamin D is a steroid-derived hormone that is obtained
from 7-dehydrocholesterol with ultraviolet light in the skin.
Approximately 95% of vitamin D is synthesized in the skin
under the influence of sunlight exposure [3]. Non-classical
effects of vitamin D are grouped under 3 main headings:
regulation of hormone secretion, immune function, and pro-
liferation and differentiation of the cell. Active vitamin D
plays an important role in maintaining normal bone mineral
homeostasis and insulin secretion [4]. Vitamin D intake and
serum 25-hydroxyvitamin D (25 (OH) D) levels are associated
with obesity, metabolic syndrome, insulin resistance, diabetes,
hypertension, cardiovascular diseases, polycystic ovary syn-
drome, fatty liver disease, and chronic renal failure [5].
Vitamin D deficiency is a worldwide public health prob-
lem, it increases the risk of metabolic syndrome [6]. Vita-
min D deficiency plays a key role in the pathophysiology of
risk factors of metabolic syndrome which affects the cardio-
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vascular system, increases insulin resistance and obesity, stim-
ulates the renin-angiotensin-aldosterone system that causes
hypertension. The discovery of vitamin D receptor expressed
ubiquitously in almost all body cells such as immune, vascu-
lar and myocardial cells, pancreatic beta cells, neurons, and
osteoblasts suggests involvement of vitamin D mediated ef-
fects on metabolic syndrome. Moreover, vitamin D deficiency
as well as cardiovascular diseases and related risk factors,
frequently co-occur. This underlines the importance of un-
derstanding the role of vitamin D in the context of metabolic
syndrome [7]. A decrease in serum 25 (OH) D vitamin level
in hemodialysis is known [8] and the study that shows the re-
lationship between vitamin D levels and metabolic syndrome
is linked in a recent study only [9–11].
Objective: We aimed at the assessment of the relation-
ship between serum vitamin D levels and metabolic syndrome
components in hemodialysis patients.
Materials and Methods
This study was performed with the participation of 80 pa-
tients between September 2017-December 2017; patients have
been undergoing hemodialysis in the dialysis unit of Erzin-
can Mengücek Gazi Education and Research Hospital for at
least 6 months three times a week, and their mean age was
56.27 ± 15.80 years. Patients were excluded if they had acute
or chronic inflammation/infection, liver failure, and cancer.
All patients received Vitamin D supplements (treatment of sec-
ondary hyperparathyroidism) and phosphorus binding agent,
included in the study.
A questionnaire technique was used to collect data re-
garding patients’ general information, medical history, and
physical activity. Their height, dry weight, and waist cir-
cumference were measured. Dry weight measurements were
conducted at the end of hemodialysis. Their body mass in-
dex (BMI) was calculated by dividing their body weight by
the square meter of height [12]. Doing or not doing regular
sports/exercise, sport/exercise type, frequency, and duration
were investigated for physical activity status.
The blood samples were collected in advance of the hemo-
dialysis. Biochemical parameters as serum 25 (OH) D, lipid
profile, fasting blood glucose (FPG), phosphorus (P), albu-
min, hemoglobin, parathyroid hormone (PTH), and C-reactive
protein (CRP) were extracted from patient files. 25 (OH) D
and parathyroid hormone were analyzed in Siemens Advia-
Centaur XP using a chemiluminescent immunometric assay
method [13]; lipid profile, FBG, calcium (Ca), P, and albu-
min were analyzed in a Beckman Coulter with model number
AU640 using a photometric method [14]. C-reactive pro-
tein was analyzed in Siemens Bn II using the nephelometer
method [15].
The metabolic syndrome status was defined by the Na-
tional Cholesterol Education Program Adult Treatment Panel III
(NCEP-ATP III). According to NCEP-ATP III guidelines,
metabolic syndrome was diagnosed with abdominal obesity
(waist circumference > 102 cm for men or > 88 cm for
women), fasting triglyceride levels ≥ 150 mg/dl, reduced
high-density lipoprotein cholesterol (HDL-C < 50 mg/dl
for women or < 40 mg/dl for men), blood pressure of sys-
tolic ≥ 130 mmHg and diastolic ones ≥ 85 mmHg, fasting
blood glucose ≥ 100 mg/dl as three or more out of five factors
to establish the diagnosis of metabolic syndrome [16].
Vitamin D status was evaluated by serum 25 (OH) vita-
min D levels according to the National Kidney Foundation’s
Kidney Disease Outcomes Quality Initiative (KDOQI). Severe
vitamin D deficiency with 25 (OH) vitamin D < 5 ng/ml; mild
vitamin D deficiency with 25 (OH) vitamin D 5-15 ng/ml;
vitamin D insufficiency with 25 (OH) vitamin D 16-30 ng/ml
and vitamin D sufficiency with 25 (OH) vitamin D > 30 ng/ml
were categorized [17].
Statistical analysis
Statistical analysis of the data was performed with the use
of SPSS version 21.0 (SPSS Inc., Chicago, USA). Data are
presented as mean ± standart deviation (SD) for numeric
variables and percentages for categoric variables. The ”Mann-
Whitney U Test” and ”Kruskal Wallis H-Test” were used for
group comparisons. The Pearson correlation analysis was
used to find the relationship between two variables. To exam-
ine the relationship between vitamin D status and metabolic
syndrome and metabolic syndrome components, multivari-
ate logistic regression models were used. Results at 95%
confidence interval, p values of < 0.05 were accepted as sta-
tistically significant [18].
Results
The study included 51 (63.7%) male and 29 (36.3%)
female hemodialysis patients whose average age was
56.27 ± 15.80 years. Patients were on dialysis for a me-
dian of 4.22 ± 2.86 years. According to NCEP-ATP III cri-
teria, metabolic syndrome was identified in 48 (48.4%) pa-
tients. Age, duration of dialysis, anthropometric measure-
ments, and biochemical parameter levels of hemodialysis pa-
tients with and without metabolic syndrome are represented
in Table 1. A statistically significant difference was observed
in dry weight, BMI, waist circumference, triglyceride, and
HDL-C levels in hemodialysis patients with and without
metabolic syndrome (p < 0.05). Dry weight, BMI, waist cir-
cumference, serum triglycerides were significantly higher and
HDL-C levels were lower in patients with metabolic syndrome
than in other groups.
According to physical activity status, 30.7% of patients
performed regular sports/exercise, it was seen that it
takes > 30 minutes/day and 3 days/week in patients who
do regular sports/exercise.
Serum 25 (OH) vitamin D levels were evaluated according
to National Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative (KDOQI); 35.0% of patients had severe vi-
tamin D deficiency, 37.4% of patients had mild vitamin D
deficiency, 18.8% of patients had vitamin D insufficiency and
8.8% of patients had vitamin D sufficiency (> 30 ng/ml),
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Table 1. Anthropometric measurements and biochemical parameter levels of hemodialysis patient with and without metabolic
syndrome.
Parameters Metabolic syndrome(+) Metabolic syndrome(-) p-value39 (49%) 41 (51%)
Age (year) 55.92±13.99 56.61±17.51 0.413
Duration of dialysis (year) 3.76±2.68 4.67±2.98 0.151
Dry weight (kg) 76.34±13.12 63.30±12.82 <0.001*
Body mass index (kg/m2)
Male 26.32±3.31 23.76±3.81 0.009*
Female 30.38±5.70 21.77±3.68 0.010*
Waist circumference (cm)
Male 100.35±8.64 91.90±9.78 0.001*
Female 100.89±12.18 81.50±13.04 0.002*
Systolic blood pressure(mmHg) 127.94±27.35 122.68±23.56 0.300
Diastolic blood pressure (mmHg) 73.74±20.03 69.51±10.23 0.230
Fasting plasma glucose (mg/dL) 133.73±58.24 115.14±85.43 0.300
Cholesterol (mg/dL) 183.00±40.56 166.36±43.10 0.052
Triglycerides (mg/dL) 231.67±103.06 159.97±120.50 <0.001*
Low density lipoprotein cholesterol (mg/dL) 106.14±35.61 93.73±32.36 0.103
High density lipoprotein cholesterol (mg/dL) 33.78±6.76 38.67±9.76 0.042*
Uric acid (mg/dL) 6.44±1.34 6.07±1.89 0.310
Albumin (mg/dL) 3.95±1.02 3.95±0.85 0.999
Phosphoros (mmol/L) 4.91±1.15 5.19±1.42 0.334
25(OH)D (nmol/L) 12.30±1.49 11.21±1.41 0.601
Hemoglobin (g/L) 11.86±1.27 11.77±2.01 0.487
Parathyroid hormone (pg/mL) 579.95±82.54 798.44±92.07 0.061
C-reactive protein (mg/dL) 11.75±2.85 10.40±1.92 0.703
Notes: *p < 0.05, Mann-Whitney U Test.
serum 25 (OH) D as a deficiency (mean 11.74 ± 81.42 nmol)
was determined. Anthropometric measurements and biochem-
ical parameter levels of hemodialysis patients according to
serum 25 (OH) D level are represented in Table 2. There was
no statistically significant difference in age, dialysis duration,
BMI, waist circumference, systolic blood pressure, diastolic
blood pressure, fasting blood glucose, cholesterol, triglyc-
erides, HDL-C, low-density lipoprotein cholesterol (LDL-C),
uric acid, PTH, and CRP levels (p > 0.05); only there was
a significant difference in waist circumference (p < 0.05)
in patients whose Vitamin D status was evaluated accord-
ing to severe deficiency, mild deficiency, insufficiency and
sufficiency. There was no significant relationship between
serum 25 (OH) D level and waist circumference, systolic
blood pressure, diastolic blood pressure, fasting blood sugar,
triglycerides, and HDL-C.
As shown in Table 3, vitamin D insufficiency was signifi-
cantly associated with metabolic syndrome and central obesity.
No associations between severe deficiency, mild deficiency,
and insufficiency and raised triglycerides, reduced HDL-C,
raised blood pressure, or raised fasting plasma glucose were
identified.
Discussion
In the study which planned to evaluate the relationship be-
tween serum 25 (OH) D and metabolic syndrome compo-
nents in hemodialysis patients, metabolic syndrome was iden-
tified in 48 (48.4 %) patients. In a study of hemodialysis
patients, metabolic syndrome was identified in 61 (56.5%)
of patients according to NCEP-ATP III criteria [19]. In an-
other study, according to the International Diabetes Federation
(IDF) criteria for metabolic syndrome, 241 (38.2%) hemodial-
ysis patients had metabolic syndrome [20]. There were 115
hemodialysis patients evaluated by NCEP-ATP III and the In-
ternational Diabetes Federation (IDF) criteria; metabolic syn-
drome was identified according to NCEP-ATP III 41.7 %
and IDF 42.6% [21]. Metabolic syndrome was 50.0% in
100 hemodialysis patients according to NCEP-ATP III crite-
ria [22]. Vogt and others identified metabolic syndrome in
98 (74.5%) patients according to IDF criteria [23]. In another
study, according to NCEP-ATP III 80 (24.7%) hemodialysis
patients had metabolic syndrome [24]. Ahmadi and others
performed a study with the participation of 145 hemodialysis
patients, and provided that metabolic syndrome was identified
according to IDF criteria 53.1 % [9]. In 143 hemodialysis
patients, metabolic syndrome was identified according to IDF
criteria 45.5% [10]. In another study, according to IDF cri-
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Table 2. Anthropometric measurements and biochemical parameter levels of hemodialysis patients according to serum 25
(OH) D level.
Vitamin D status
Parameters Severe deficiency Deficiency Insufficiency Sufficiency p-value28(35%) 30(38%) 15(19%) 7(8%)
Age (year) 54.64±15.61 56.43±15.83 58.13±17.10 58.14±16.44 0.965
Duration dialysis (year) 4.67±2.65 4.41±2.60 3.38±0.92 3.42±1.18 0.107
Body mass index (kg/m2) 24.87±3.87 25.12±6.15 24.56±5.82 24.16±6.78 0.809
Waist circumference (cm) 94.75±10.43 92.43±15.52 96.34±18.42 93.36±14.70 0.006*
Systolic blood pressure (mmHg) 124.35±31.10 117.56±18.78 124.46±24.56 116.62±25.13 0.844
Diastolic blood pressure (mmHg) 69.34±9.91 71.23±9.54 73.01±14.13 70.12±10.89 0.847
Fasting plasma glucose (mg/dL) 117.89±57.96 104.09±36.12 120.55±64.56 117.12±59.73 0.920
Cholesterol (mg/dL) 159.86±32.67 175.18±44.12 182.45±58.80 183.89±74.32 0.154
Triglycerides (mg/dL) 159.30±81.33 154.29±58.54 194.77±111.34 188.09±113.93 0.425
High density lipoprotein choles-
terol (mg/dL) 37.24±9.55 36.18±10.29 37.24±9.21 38.39±14.10 0.444
Low density lipoprotein choles-
terol (mg/dL) 95.98±24.06 109.78±34.13 107.67±69.18 102.68±36.64 0.225
Uric acid (mg/dL) 5.81±1.27 6.58±2.49 6.25±1.35 6.20±0.66 0.734
Parathyroid hormone (pg/mL) 843.70±484.56 727.58±614.66 707.98±707.89 157.64±71.25 0.299
C-reactive protein (mg/dL) 17.96±14.70 23.11±18.87 12.58±10.29 15.24±12.72 0.582
Notes: p > 0.05, Kruskal Wallis Test.
Table 3. Association of vitamin D status with the metabolic syndrome and components of the metabolic syndrome among the
hemodialysis patients.
Vitamin D status
Severe deficiency Mild deficiency Insufficiency
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Adjusted for age and sex
Metabolic syndrome 2.70 (1.02-9.36) 0.300 2.41 (0.5-9.96) 0.921 3.34 (1.20-8.60) 0.030*
Central obesity 0.65 (0.39-1.28) 0.816 0.72 (0.50-1.49) 0.218 0.98 (0.65-1.78) 0.002*
Raised triglycerides 1.54 (1.36-1.80) 0.148 1.45 (0.95-2.21) 0.090 1.53 (1.15-2.48) 0.876
Reduced high-density lipoprotein
cholesterol 0.85 (0.63-1.80) 0.645 1.05 (0.84-2.12) 0.432 0.93 (0.61-1.98) 0.149
Raised blood pressure 1.57 (0.20-1.71) 0.078 0.95 (0.23-2.38) 0.110 1.51 (1.30-1.88) 0.315
Raised fasting plasma glucose 1.13 (0.56-2.05) 0.322 1.22 (0.76-2.49) 0.087 0.92 (0.58-2.23) 0.675
Notes: In all models, vitamin D sufficiency was designated as the reference category (odds ratio = 1.00).
teria, 90 (25.3%) hemodialysis patients had metabolic syn-
drome [11]. In studies, the prevalence of metabolic syndrome
in hemodialysis patients varies according to the diagnostic
criteria for metabolic syndrome and the number of patients [9–
11, 19–23]. It appears, that the prevalence of metabolic syn-
drome among patients on hemodialysis was nearly half in
different studies [9, 10, 21, 22] and metabolic syndrome iden-
tified in this study (48.4%), were similar.
A recent meta-analysis showed that different components
in the metabolic syndrome negatively affect the kidney in
different proportions in terms of proteinuria, and it showed
their effect in descending order to be hypertension, hyper-
triglyceridemia, low HDL-C, abdominal obesity, and im-
paired glucose intolerance [25]. Also supporting studies made
in [9, 10, 21, 24, 26], dry weight, BMI, waist circumference,
serum triglycerides were significantly higher and HDL-C lev-
els were lower in patients with metabolic syndrome than other
groups. As in this study, BMI is also high in patients with
metabolic syndrome (p < 0.05), is an independent predictor of
metabolic syndrome in hemodialysis patients without diabetes
and dyslipidemia [9, 15, 22, 24, 27]. These discrepancies in
the results of different studies could be attributed to the differ-
ent populations and healthcare settings between these studies
and the current study.
Vitamin D deficiency is a worldwide public health prob-
lem seen in hemodialysis patients. In this study, according to
the serum levels of vitamin D 35.0% of patients had severe
vitamin D deficiency, 37.4% of patients had mild vitamin D
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deficiency, 18.8% of patients had vitamin D insufficiency and
8.8% of patients had vitamin D sufficiency (> 30 ng/ml),
serum 25 (OH) D as a deficiency (mean 11.74 ± 81.42 nmol)
was determined and vitamin D deficiency/insufficiency is
found in near almost all of the patients (91.2%). To deter-
mine the vitamin D deficiency in hemodialysis patients in
another study performed with the participation of 187 pa-
tients, mean serum 25 (OH) D level was 11.7 ± 7.5 ng/ml;
just sufficiency in 4%, deficiency in 73%, insufficiency in 23%
of patients was found [8]. In a study with the participation of
47 patients to determine serum vitamin D level in hemodialy-
sis patients, deficiency in 72.4% of patients, insufficiency in
23.4% of patients, and sufficiency in 4.3% of patients were
identified [28]. In a study with the participation of 145 pa-
tients, mean serum vitamin D levels of 24.7 ± 16.1 ng/ml,
severe deficiency in 3.4% of patients, deficiency in 31% of
patients, insufficiency in 36.6% of patients, and sufficiency in
29 % of patients were found [9]. Pinghua and others found
that according to the levels of 25 (OH) D3, patients were in-
cluded into sufficient group 33 (23.1%), insufficient group 69
(48.2%), and deficient group 41 (28.7%) [10]. Kara and others
showed that patients with serum 25 (OH) D levels < 20 ng/ml,
were classified as those having a vitamin D deficiency 83
(64.3%) and those with serum 25 (OH) D levels ≥ 20 ng/ml
were classified as having normal vitamin D levels 46 (35.7%).
The mean serum 25 (OH) D levels were 11.13 ± 3.60 ng/ml
in the deficient group and 27.04 ± 7.20 ng/ml in the normal
group [29]. The results of this study are in line with the results
of studies on this issue [8].
Although it is known that vitamin D deficiency increases
the risk of metabolic syndrome [6], low serum vitamin D
levels in were found to be associated with the metabolic syn-
drome in studies [9, 10], but another study concluded that
there is a lack of association between serum 25 (OH) vita-
min D concentrations and metabolic syndrome in hemodialy-
sis patients [11]. There was a relationship between vitamin D
deficiency and components of metabolic syndrome as cen-
tral obesity and fasting blood glucose [9]. Low 25 (OH) D3
level negatively correlated with abnormal metabolic factors
central obesity, raised TG, reduced HDL-C, raised SBP, and
raised FBG [10]. In another study, both vitamin D mild de-
ficiency and insufficiency were found to be significantly as-
sociated with central obesity [11]. In this study, vitamin D
levels in hemodialysis patients were deficiency/insufficiency
and vitamin D insufficiency was significantly associated with
metabolic syndrome and central obesity.
Vitamin D deficiency is lower in obese individuals due to
insufficient intake of vitamin D, dressing more closed than
normal-weight individuals, and due to less outdoor physical
activity, and because of their high fat mass, vitamin D stor-
age rate and consequently decrease in bioavailability, obese
individuals are in subcutaneous adipose tissue. The levels of
25-hydroxylase and 1-alpha hydroxylase, which are the en-
zymes that activate vitamin D, are considered to be decreased.
In addition, vitamin D deficiency in obese individuals can
support lipogenesis and weight gain [30].
Conclusions
An increase was seen in BMI, waist circumference, triglyc-
eride, and HDL levels which components of the metabolic
syndrome in hemodialysis patients. Deficiency/insufficiency
of serum vitamin D levels was in hemodialysis patients, and
vitamin D insufficiency was significantly associated with
metabolic syndrome and central obesity. Appropriate nutri-
tion programs to patients should be prepared for hemodialysis
patients to achieve their ideal weight and to control which
is a component of metabolic syndrome, blood sugar, and
triglyceride levels and follow-up should be done regularly.
The physician gave vitamin D supplements to patients who
diagnosed deficiency/insufficiency of vitamin D in hemodialy-
sis patients, overcoming deficiency/insufficiency of vitamin D.
Sun exposure is the most important determinant of vitamin D
in hemodialysis patients. Seasonal variation is an important
parameter affecting sun exposure. Peak vitamin D levels are
in autumn or the end of summer and the lowest levels are in
spring or the end of winter. Sun exposure level is also impor-
tant. Sun exposure time > 6 hours/week or active physical
activity > 30 min/day and 3 days/week may have a positive
impact on both their vitamin D levels and the metabolic syn-
drome.
Prospects of Further Researches
The limitations of this study, small sample and to conduct
this study in a single-center, unfavorable evaluation of sun
exposure conditions are the shortcomings of this investiga-
tion. Long-term randomized controlled trials are needed to
determine the relationship between metabolic syndrome com-
ponents and vitamin D levels.
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